AUG 13, 2015 10:25 AM PDT

Beating Obesity

WRITTEN BY: Ilene Schneider

You might have been told that cannabis makes you hungry. A team of researchers is finding a way to use it in a weight loss pill. Why is that so important?



Researchers test zebrafish and human cells to test the cannabis-vitamin A combination they want to use as a weight loss drug.



According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than two-thirds (68.8 percent) of adults are considered to be overweight or obese. Additionally, more than one-third (35.7 percent) of adults are considered to be obese, more than 1 in 20 (6.3 percent) are extremely obese, nearly 3 in 4 men (74 percent) are considered to be overweight or obese and 8 percent of women are considered to be extremely obese. The prevalence of obesity is similar for both men and women (about 36 percent (https://www.niddk.nih.gov/health-information/health-statistics/Pages/overweight-obesity-statistics.aspx).



Medical researchers, who are part of Deakin University Medical School’s Metabolic Research Unit have taken the unusual approach of combining two pharmaceuticals – extracted from cannabis and vitamin A – with the eventual aim of developing a drug to treat obesity. They “used zebrafish and human cells to test the effect of the Endocannabinoid system (an active compound of cannabis which plays a role in appetite regulation and fat formation) and the Retinoic Acid Pathway (an active component of vitamin A) on reducing the deposit of fat,” according to an article in Drug Discovery & Development (https://www.dddmag.com/news/2015/08/medical-researchers-step-closer-developing-anti-obesity-pill?et_cid=4738815&et_rid=45505806&location=top).



As explained by Dr Yann Gibert, the Head of the Metabolic Genetic Diseases Research Laboratory, "The results of our study show, for the first time, that particular compounds in cannabis and vitamin A can work together to reduce the deposit of lipids (fats). This finding opens up exciting opportunities to potentially treat obesity without the need for invasive surgery."



He added, "The complementary actions of the Endocannabinoid system and Retinoic Acid Pathway in reducing fat deposits have the potential to treat obesity in a safer and more effective way than if they were used independently. This approach only focuses on fat, and avoids effects on the brain, which has been a concern in previous research involving cannabis."



While it is understood that the cannabis system regulates appetite, adverse side effects have kept researchers from using drug in humans for medical purposes. Dr. Gilbert’ss research has discovered a method of potentially removing these negative effects by using the two systems together and at a reduced dosage. Inasmuch as this study has shown that these two pathways can work together during fat accumulation, the method of doing so is not clear.

Dr Gibert stated that the team is planning to test the effectiveness of the drug further and to determine whether there are side effects. He concluded, "If there are no side effects, new therapeutics could be ready for human use within five years."

About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 13, 2020
Cannabis Sciences
Over Half of CBD Products Falsely Labeled
JUL 13, 2020
Over Half of CBD Products Falsely Labeled
Tests conducted by the US Food and Drug Agency (FDA) have found that 55% of cannabidiol (CBD) products contain significa ...
AUG 10, 2020
Cannabis Sciences
Cannabis Use During Pregnancy Linked to Autism
AUG 10, 2020
Cannabis Use During Pregnancy Linked to Autism
Researchers from The Ottawa Hospital in Ontario, Canada, have found that children born to mothers who used cannabis whil ...
SEP 16, 2020
Health & Medicine
72% of Canadian Cannabis Users Say They Don't Fit Stoner Stereotype
SEP 16, 2020
72% of Canadian Cannabis Users Say They Don't Fit Stoner Stereotype
    Nearly three-quarters  (72 percent) of  cannabis users simply don’t see themselves as fitt ...
OCT 05, 2020
Health & Medicine
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
OCT 05, 2020
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
Even with the best anti-nausea medications one in three patients receiving chemotherapy experiences vomiting, and about ...
OCT 21, 2020
Cannabis Sciences
Exercise Reverses Learning Impairments from Cannabinoid Issues
OCT 21, 2020
Exercise Reverses Learning Impairments from Cannabinoid Issues
While cannabinoids usually get attention for their recreational effects, these molecules play a role in several other pr ...
NOV 14, 2020
Cannabis Sciences
Half of CBD Users Test Positive for THC in Urine Tests
NOV 14, 2020
Half of CBD Users Test Positive for THC in Urine Tests
Despite the growing popularity of cannabidiol (CBD) products, there has been little research directly assessing whether ...
Loading Comments...